Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate
Abstract
MP0250 is a multi-domain drug candidate currently being tested in clinical trials for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum albumin (HSA) DARPin® domains within a single polypeptide chain. While there is first clinical validation of a single-domain DARPin® drug candidate, little is known about DARPin® drug candidates...
Paper Details
Title
Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate
Published Date
Oct 16, 2017
Journal
Volume
9
Issue
8
Pages
1262 - 1269
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History